ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe ADVANZ PHARMA’s response to the reversal of the suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The conditional marketing authorisation...

ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe The European Commission’s decision to revoke the OCALIVA®...

ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) OCALIVA® is the only farnesoid X...